Atrium Therapeutics, Inc. (RNA) News
Track canonical SquawkNews coverage tagged to RNA, Atrium Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Atrium Therapeutics reports Second Quarter 2026 financial results
Atrium Therapeutics (RNA) reports its Second Quarter 2026 financial results, per TradeXchange Newsdesk, with no figures or additional detail included in the feed.
EARNINGS | Aug 13, 2026, 08:45 PM UTC
L
MRVI Maravai unit TriLink wins China patent for CleanCap mRNA capping technology Maravai LifeSciences’ TriLink unit secured a newly issued C
MRVI Maravai unit TriLink wins China patent for CleanCap mRNA capping technology Maravai LifeSciences’ TriLink unit secured a newly issued China patent for CleanCap mRNA capping technology, strengthening IP Protection in
GEOPOLITICS | Jul 20, 2026, 08:06 PM UTC
L
Atrium Therapeutics Says FDA Clears Phase 1/2 Trial of ATR 1072 in PRKAG2 Syndrome
() -- Atrium Therapeutics (RNA) said Tuesday the US Food and Drug Administration cleared its investigational new drug application for its lead product candidate ATR 1072, allowing the company to advance a phase 1/2 clini
REGULATION | Jul 14, 2026, 11:18 AM UTC
L
Atrium Therapeutics announces FDA clearance of ATR 1072 IND application
Atrium Therapeutics...
REGULATION | Jul 14, 2026, 10:36 AM UTC